HSTO Histogen Inc

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering

SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code (“Chapter 11”) in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders.

Histogen intends to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate. The Company announced on Sept. 18, 2023, that it had discontinued further development and would seek approve for a Plan of Dissolution.

Histogen is represented by DLA Piper, LLP as its legal counsel and Armanino LLP as its financial advisor.

ABOUT HISTOGEN

Histogen Inc. was a clinical-stage therapeutics company focused on developing potential clinical and preclinical drugs for a variety of antiapoptotic and anti-inflammatory effects.







MEDIA CONTACT
Martin Stein
AMF Media Group
EN
18/04/2024

Underlying

HSTOHistogen Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Histogen Inc

 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-...

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code (“Chapter 11”) in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders. ...

April 18, 2024 1 EN
 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen Announces Second Adjournment of Special Meeting of Stockholde...

Histogen Announces Second Adjournment of Special Meeting of Stockholders Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO), today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange C...

December 14, 2023 1 EN
 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen Announces Adjournment of Special Meeting of Stockholders

Histogen Announces Adjournment of Special Meeting of Stockholders Meeting Adjourned to December 14, 2023 at 8:00 a.m. PT SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO) today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 18, 2023 (the “Proxy Statement”). The reconvened Special Meeting on December 14, 2023 will...

December 5, 2023 1 EN
 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen Announces Board Approval of Complete Liquidation and Dissolut...

Histogen Announces Board Approval of Complete Liquidation and Dissolution SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of D...

September 18, 2023 1 EN
 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen to Explore Strategic Alternatives

Histogen to Explore Strategic Alternatives SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternat...

July 5, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch